FDA Asks Shire, Protalix to Speed Gaucher’s Drugs Submissions

Drug Industry Daily
A A
The FDA has asked two companies, Protalix Biotherapeutics and Shire, to submit treatment protocols for separate experimental Gaucher’s disease medicines to speed patient access to the drug — and the agency plans a 30-day review.

To View This Article:

Login

Subscribe To Drug Industry Daily